Kalshi Launches Clinical-Trial Betting Markets With AppliedXL, Starting With a Small Number
Updated
Updated · STAT · Jul 16
Kalshi Launches Clinical-Trial Betting Markets With AppliedXL, Starting With a Small Number
3 articles · Updated · STAT · Jul 16
Summary
Kalshi said Thursday it will begin offering prediction markets on biopharma clinical trials and regulatory approvals, extending event-based betting into drug development.
A small initial slate of markets was selected with AppliedXL, a technology company that tracks and forecasts clinical-trial outcomes.
The move pushes prediction markets beyond sports, politics and entertainment into a heavily watched sector where trial results and FDA decisions can sharply move company valuations.
As betting on drug trials grows, where is the line between market insight and gambling on human health?
Facing a potential ban on its core business, is Kalshi's biopharma expansion a brilliant pivot or a desperate gamble?
In the race to predict drug success, will the wisdom of the crowd be outsmarted by artificial intelligence?
Kalshi and AppliedXL Launch $24B Clinical Trial Prediction Markets: AI, Ethics, and the Future of Biotech Betting
Overview
In July 2026, Kalshi and AppliedXL launched new prediction markets for betting on biotech clinical trials and drug approvals, aiming to bring transparency to a sector where the odds of drug success are usually hidden and information is often incomplete. Developing a drug is extremely costly, and companies’ futures can depend on a single trial, yet most success estimates remain confidential. Kalshi’s markets address this information gap by creating a real-time, public consensus on drug prospects. AppliedXL’s AI-driven prediction system adds nuance by analyzing trial outcomes beyond simple success or failure, offering more detailed and relevant forecasts for investors and the public.